RT Journal Article
T1 Role of asymptomatic bacteriuria on early periprosthetic joint infection after hip hemiarthroplasty. BARIFER randomized clinical trial.
A1 Rodríguez-Pardo, Dolors
A1 Del Toro, María Dolores
A1 Guío-Carrión, Laura
A1 Escudero-Sánchez, Rosa
A1 Fernández-Sampedro, Marta
A1 García-Viejo, Miguel Ángel
A1 Velasco-Arribas, María
A1 Soldevila-Boixader, Laura
A1 Femenias, Magdalena
A1 Iribarren, José Antonio
A1 Pulido-Garcia, María Del Carmen
A1 Navarro, María Dolores
A1 Lung, Mayli
A1 Corona, Pablo S
A1 Almirante, Benito
A1 Pigrau, Carles
K1 Asymptomatic bacteriuria
K1 Early-periprosthetic joint infection
K1 Fosfomycin-trometamol
K1 Hip hemiarthroplasty
AB To evaluate preoperative asymptomatic bacteriuria (ASB) treatment to reduce early-periprosthetic joint infections (early-PJIs) after hip hemiarthroplasty (HHA) for fracture. Open-label, multicenter RCT comparing fosfomycin-trometamol versus no intervention with a parallel follow-up cohort without ASB. early-PJI after HHA. Five hundred ninety-four patients enrolled (mean age 84.3); 152(25%) with ASB (77 treated with fosfomycin-trometamol/75 controls) and 442(75%) without. Despite the study closed without the intended sample size, ASB was not predictive of early-PJI (OR: 1.06 [95%CI: 0.33-3.38]), and its treatment did not modify early-PJI incidence (OR: 1.03 [95%CI: 0.15-7.10]). Neither preoperative ASB nor its treatment appears to be risk factors of early-PJI after HHA. ClinicalTrials.gov Identifier: Eudra CT 2016-001108-47.
YR 2021
FD 2021-04-16
LK http://hdl.handle.net/10668/17592
UL http://hdl.handle.net/10668/17592
LA en
DS RISalud
RD Apr 19, 2025